Magazine
In response to the coronavirus pandemic, Christian Angermayer—the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.
Magazine
The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.
Magazine
“The Corona Virus is a necessary purge of what is no longer in resonance,” Trinity de Guzman wrote in a recent email to his followers.
Magazine
A long-fought battle for access to peyote, and a dwindling population in the United States has led Native American Church members and peyote conservationists to request that peyote be left out of decriminalization efforts.
Magazine
As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.
Magazine
Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.
Magazine
After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.
Magazine
The new leaders of the psychedelic medicalization industry seem to see themselves as above their own self-proposed rules.
Magazine
“Play the field right and there’s money to be made even off some of the shit companies purely based on the wave.”
Magazine
Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?
Magazine
Can psychedelic civil disobedience really stimulate systemic reorganization?
Magazine
Our statement on a recent Chacruna article by Dr. Bia Labate.